• News
  • Stock Screener
  • Small Caps
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Review
  • X (Twitter)
  • LinkedIn
Home
·
Contributors
·
Igor Klushnev
Klushnev Igor

Igor Klushnev

Writes about:

    NVIDIA Corporation

    NVDA
    6

    Amazon.com, Inc.

    AMZN
    5

    Salesforce, Inc.

    CRM
    6
Share

Articles: 4

Revolution Medicines in April announced unprecedented results for its pancreatic cancer drug. Its shares have risen nearly 300% in a year. Photo: LinkedIn page
Review·21.04.2026 13:49

How oncology company Revolution Medicines monetized a year of operations in 48 hours

  • RVMD
The transition from selling software to selling AI agents will change the logic of monetization of companies. Photo: mohammadhridoy1 / Shutterstock.com
Review·29.03.2026 18:01

AI agents decide everything: 10 companies that will benefit from moving to an AaaS model

  • NVDA
  • NOW
  • PLTR
  • AVGO
  • +6
Hedge funds are not running for cover: how they are preparing for the start of the business season
Review·18.08.2025 13:00

Hedge funds are not running for cover: how they are preparing for the start of the business season

  • NVDA
  • KKR
  • META
Nvidias race: does the company have a chance to grow its capitalization to $5 trillion?
Review·03.06.2025 17:05

Nvidia's race: does the company have a chance to grow its capitalization to $5 trillion?

  • NVDA
  • AMD
  • AMZN
X-channel

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2025